Due to the complexity of multifactorial diseases, single-target drugs do not always exhibit
satisfactory efficacy. Recently, increasing evidence indicates that simultaneous modulation …

Combining existing drug therapy is essential in developing new therapeutic agents in
disease prevention and treatment. In preclinical investigations, combined effect of certain …

Therapeutic options for pulmonary arterial hypertension (PAH) have increased over the last
decades. The advent of pharmacological therapies targeting the prostacyclin, endothelin …

Alveolar hypoxia is the most prominent feature of high altitude environment with well-known
consequences for the cardio-pulmonary system, including development of pulmonary …

Pulmonary hypertension is a progressive and often fatal cardiopulmonary condition
characterised by increased pulmonary arterial pressure, structural changes in the pulmonary …

The low-density lipoprotein receptor (LDLR) gene family includes LDLR, very LDLR, and
LDL receptor–related proteins (LRPs) such as LRP1, LRP1b (aka LRP-DIT), LRP2 (aka …

The global outbreak of COVID-19 viral infection is associated with the absence of specific
drug (s) for fighting this viral infection. About 10 million people are already infected, about …

Pulmonary arterial hypertension (PAH) is a rare disease associated with abnormally
elevated pulmonary pressures and right heart failure resulting in high morbidity and …

Abstract Pulmonary Arterial Hypertension (PAH) is the progressive increase in mean
pulmonary arterial pressure (mPAP)(≥ 20 mmHg at rest). Current treatment strategies …

Cancer therapies are being considered for treating rare noncancerous diseases like
pulmonary hypertension (PH), but effective computational screening is lacking. Via …